UNSPSC 51382101: Araprofen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BIQ52YQ7VG. European Medicines Agency schedules Araprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05552MIG. Araprofen generally arises in the molecular formula C16H15NO4. The term ARAPROFEN is an International Non-Proprietary Name or INN. ARAPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule araprofen under HS 29224995 and SITC 51465. As of Q4 2014, ARAPROFEN remains the US FDA Preferred Term for this commodity. Araprofen bears US NLM identifiers UMLS ID C2346851 and NCI Concept Code C73075. SMILES: OC(=O)C(C1CCC(NC2C(CCCC2)C(=O)O)CC1)C.

UNSPSC 51382101 Araprofen is a Commodity-tier code that nominally covers a specific nonsteroidal anti-inflammatory drug, but recent state and local solicitations tagged to this code focus on naloxone, drug deactivation systems, and broader pharmaceutical procurement including generic multi-source drugs and over-the-counter products. State and local governments use this code framework to procure emergency-response medications, community health supplies, and multi-jurisdictional pharmaceutical distribution contracts. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, which serves Oregon and other participating members). The actual procurement activity spans naloxone for opioid-overdose response, safe drug deactivation and disposal systems, and broader-based pharmaceutical sourcing through authorized wholesaler networks.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida released an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving state agencies and self-insured employee health plans, with no formal award timeline specified at the RFI stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson to participating state and local facilities, with a response deadline of March 26, 2026, and contract effectiveness of July 1, 2026. MMCAP requires vendors to maintain commercial general liability of $5,000,000 per occurrence, comply with FDA requirements and current Good Manufacturing Practices, and pay a 3 percent administrative fee on all purchases.